Biogen Idec And Swedish Orphan Biovitrum Announce First Patient Dosed In Global Registrational Trial Of Long-Acting Hemophilia B Therapy

Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum (STO: BVT) announced that the first patient was dosed in a registrational, open-label, multicenter trial designed to evaluate the safety, pharmacokinetics and efficacy of the companies’ long-acting, recombinant Factor IX Fc fusion protein (rFIXFc) in hemophilia B patients…

More: continued here

Filed under: Blood on January 25th, 2010